small win: MASH stopped being a problem at week 43
small win: MASH stopped being a problem at week 43. Full detail below, and I have tried to keep the editorialising out of it. Imaging-derived liver fat fraction is a surrogate. It correlates with histology imperfectly, and a trial reporting one is not reporting the other. Histological endpoints in this field are…
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost no
Disagreeing with this bit: that number comes from a different programme with a different population.
Disagreeing with this bit: that number comes from a different programme with a different population.
joaquin_ivaturi is right that biopsy and imaging endpoints are not interchangeable.
Small fix — dual agonist, GLP-1 and glucagon. No GIP arm in this molecule.
It is a dual agonist at the GLP-1 and glucagon receptors. The glucagon arm is associated with increased energy expenditure and with effects on hepatic fat, which is why the development programme is oriented towards liver disease.
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
This. Biopsy-confirmed and imaging-suggested are different evidentiary categories and get run together constantly.